AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23938095 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 52
Study 23938095 — intervention group
Group type: COMPARATOR
Intervention: FS-LASIK (Control)
Number of subjects: 52
Study 20949349 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at target MAP of 75 mmHg
Number of subjects: 12
Study 20949349 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion at target MAP of 60 mmHg
Number of subjects: 12
Study 20949349 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at target MAP of 90 mmHg
Number of subjects: 12
Study 18187617 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (NA) 1 g 60 min before, and 0.5 g 60 and 180 min after sprint 1
Number of subjects: 7
Study 18187617 — intervention group
Group type: COMPARATOR
Intervention: Control (Con) trial
Number of subjects: 7
Study 16303987 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication utilization patterns in patients with BPD
Number of subjects: 29
Study 16303987 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods of suicidality in patients with BPD
Number of subjects: 29
Study 16303987 — intervention group
Group type: EXPERIMENTAL
Intervention: Axis III discharge diagnoses in patients with BPD
Number of subjects: 29
Study 16303987 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of overdosage as a means to end life in patients with BPD
Number of subjects: 29
Study 12745514 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacholine (MCh; 2 and 4 mg/min) and sodium nitroprusside (SNP; 5 and 10 mg/min)
Number of subjects: 108
Study 11187922 — intervention group
Group type: EXPERIMENTAL
Intervention: American therapy template with two post-remission intensification modules
Number of subjects: 90
Study 11187922 — intervention group
Group type: EXPERIMENTAL
Intervention: Third intensification module
Number of subjects: 90
Study 11187922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate injections
Number of subjects: 90
Study 11187922 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, sex, and white count >50 x 10(9)/l
Number of subjects: 90
Study 11187922 — intervention group
Group type: EXPERIMENTAL
Intervention: Rome/NCI criteria
Number of subjects: 90
Study 8884642 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus application of 25% tetracycline fiber (S + Tet)
Number of subjects: 54
Study 8884642 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus application of 2% minocycline gel (S + Min)
Number of subjects: 54
Study 8884642 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing plus application of 25% metronidazole gel (S + Met)
Number of subjects: 54
Study 8884642 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone (S)
Number of subjects: 54
Study 1858637 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension patients
Number of subjects: 79
Study 6358652 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasmapheresis
Number of subjects: 350
Study 6358652 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse therapy
Number of subjects: 350
Study 6358652 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 350
Study 6358652 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 350
Study 6358652 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibody-induced RPGN
Number of subjects: 350
Study 31295222 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV infection
Number of subjects: 245
Study 31295222 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent high-risk HPV infection
Number of subjects: 245
Study 31295222 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 and/or HPV18 types
Number of subjects: 245
Study 31295222 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident high-risk HPV infection postpartum
Number of subjects: 245
Study 31295222 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent high-risk HPV and preterm birth
Number of subjects: 245
Study 29059186 — intervention group
Group type: EXPERIMENTAL
Intervention: DEC and albendazole (single oral dose, repeated annually or semi-annually)
Number of subjects: 102
Study 26943607 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 levels measured on postoperative day 1 (PD1)
Number of subjects: 92
Study 26943607 — intervention group
Group type: EXPERIMENTAL
Intervention: S100 levels <123 pg mL-1 on PD1
Number of subjects: 92
Study 25726215 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring in a sports center (MON)
Number of subjects: 76
Study 25726215 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription at home (PRES)
Number of subjects: 76
Study 25726215 — intervention group
Group type: COMPARATOR
Intervention: Recommendation (REC)
Number of subjects: 76
Study 25726215 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 76
Study 22994049 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pretreatment (OCP), n = 53
Number of subjects: 85
Study 22994049 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OCP), n = 32
Number of subjects: 85
Study 19923550 — intervention group
Group type: EXPERIMENTAL
Intervention: IV bapineuzumab (0.15, 0.5, 1.0, or 2.0 mg/kg)
Number of subjects: 234
Study 19923550 — intervention group
Group type: EXPERIMENTAL
Intervention: IV bapineuzumab
Number of subjects: 234
Study 19923550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 17525395 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of uric acid (UA)
Number of subjects: 24
Study 17525395 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of uric acid (UA)
Number of subjects: 24
Study 17525395 — intervention group
Group type: COMPARATOR
Intervention: 5% mannitol/0.1% lithium carbonate (vehicle group)
Number of subjects: 24
Study 15217656 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg of midazolam IV 20 minutes preoperatively
Number of subjects: 88
Study 15217656 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV 20 minutes preoperatively
Number of subjects: 88
Study 11277451 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloring a single letter in Stroop tasks
Number of subjects: 312
Study 11277451 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloring a single element
Number of subjects: 312
Study 9736008 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) of residual symptoms supplemented by lifestyle modification and well-being therapy
Number of subjects: 40
Study 9736008 — intervention group
Group type: COMPARATOR
Intervention: Clinical management
Number of subjects: 40
Study 8623943 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh 3 laryngoscope
Number of subjects: 0
Study 8623943 — intervention group
Group type: COMPARATOR
Intervention: Miller 2 laryngoscope
Number of subjects: 0
Study 8623943 — intervention group
Group type: COMPARATOR
Intervention: Different anesthetists
Number of subjects: 0
Study 2571295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 0
Study 2571295 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐adrenergic blockers
Number of subjects: 0
Study 2571295 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0
Study 2571295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0
Study 2571295 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 0
Study 2571295 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (100 mg) with Hydrochlorothiazide (25 mg)
Number of subjects: 0
Study 2571295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg) with Clopamide (5 mg)
Number of subjects: 0
Study 2571295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin and Flosequinan
Number of subjects: 0
Study 180192 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical interferon inducer (CP 20961)
Number of subjects: 6
Study 180192 — intervention group
Group type: COMPARATOR
Intervention: Drug vehicle (polysorbate-80 in glycerol and saline)
Number of subjects: 6
Study 180192 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study 180192 — intervention group
Group type: COMPARATOR
Intervention: Oral lactose
Number of subjects: 6
Study 31538913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular Matrix combined with autologous platelet‐rich plasma (A‐PRP) and standardized physiotherapy
Number of subjects: 25
Study 31177276 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal Multiple Micronutrients (MMN) supplementation
Number of subjects: 108
Study 31177276 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) supplementation
Number of subjects: 108
Study 27940063 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence monitoring with customized reminders (including alarms, texts, telephone calls, and/or e‐mails)
Number of subjects: 120
Study 27940063 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring with customized reminders plus provider notification (every 2 weeks, providers received notification if adherence decreased to <90%)
Number of subjects: 120
Study 27940063 — intervention group
Group type: COMPARATOR
Intervention: Wireless pill bottle use alone (control)
Number of subjects: 120
Study 27940063 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 26164799 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term recipients (STR) group
Number of subjects: 176
Study 26164799 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term recipients group
Number of subjects: 176
Study 26164799 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Pain Disability Index
Number of subjects: 176
Study 26164799 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Disability Questionnaire
Number of subjects: 176
Study 26164799 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-Murler Score
Number of subjects: 176
Study 24432674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Tiaojing Recipe (BTR)
Number of subjects: 72
Study 24432674 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 72
Study 24432674 — intervention group
Group type: EXPERIMENTAL
Intervention: BTR + HRT
Number of subjects: 72
Study 21175995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rikkunshito (7.5 g day(-1) for 2 weeks)
Number of subjects: 9
Study 19162498 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 sympathicotomy (n=68)
Number of subjects: 141
Study 19162498 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 sympathicotomy (n=73)
Number of subjects: 141
Study 17001567 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ERCP
Number of subjects: 123
Study 17001567 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative ERCP
Number of subjects: 123
Study 16281459 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover analysis using Troxel et al.'s method
Number of subjects: 0
Study 16281459 — intervention group
Group type: COMPARATOR
Intervention: As-treated analysis
Number of subjects: 0
Study 10661479 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 4 IU/m2
Number of subjects: 20
Study 10661479 — intervention group
Group type: COMPARATOR
Intervention: placebo injections
Number of subjects: 20
Study 9104085 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical interventions in preventing major causes of morbidity and mortality in older women
Number of subjects: 164500
Study 8350309 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary clinical instruction by general internal medicine physicians
Number of subjects: 0
Study 8350309 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary clinical instruction by physical therapists
Number of subjects: 0
Study 8350309 — intervention group
Group type: COMPARATOR
Intervention: Baseline education (lecture and supervision by clinical preceptors)
Number of subjects: 0
Study 3513642 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg mefloquine, 1.5 g sulfadoxine, 75 mg pyrimethamine (MSP)
Number of subjects: 119
Study 3513642 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg quinine 8‐hourly for 3 days and 500 mg tetracycline 8‐hourly for 7 days (Q3T7)
Number of subjects: 119
Study 3513642 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg quinine 8‐hourly for 7 days and 500 mg tetracycline 8‐hourly for 7 days (Q7T7)
Number of subjects: 119
Study 31925727 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (RYGB)
Number of subjects: 40
Study 31925727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 40
Study 31925727 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with diet and exercise (Control)
Number of subjects: 40
Study 29275850 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot Mineral Trioxide Aggregate (MTA)
Number of subjects: 59
Study 29275850 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 59
Study 27523186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimuno-galactooligosaccharide (B-GOS) 5.5 g/d for 3 weeks
Number of subjects: 10
Study 27523186 — intervention group
Group type: EXPERIMENTAL
Intervention: B-GOS
Number of subjects: 10
Study 27523186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24062227 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 30 mg/kg TXA on induction of surgery (one shot [OS] group)
Number of subjects: 164
Study 24062227 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 10 mg/kg TXA followed by continuous infusion of 2 mg/kg per hour for 20 hours (one day [OD] group)
Number of subjects: 164
Study 24062227 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 164
Study 22721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile stimulation at 20 Hz and 100 Hz
Number of subjects: 0
Study 22721377 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile stimulation at 3 Hz
Number of subjects: 0
Study 22721377 — intervention group
Group type: COMPARATOR
Intervention: Tactile stimulation with visual task
Number of subjects: 0
Study 20104197 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus lower‐molecular weight heparin treatment (LT group)
Number of subjects: 265
Study 20104197 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (C group)
Number of subjects: 265
Study 18557664 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg B(12) + 2 mg folic acid + 25 mg B(6) per day
Number of subjects: 299
Study 18557664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 15949922 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg sodium valproate
Number of subjects: 33
Study 15949922 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg lithium
Number of subjects: 33
Study 15949922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11799348 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) 3-6 million units subcutaneously three to six times a week for 6 months
Number of subjects: 18
Study 11799348 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 18
Study 10223267 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (375 mg caffeine and 75 mg ephedrine)
Number of subjects: 9
Study 10223267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10223267 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study 10223267 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E (D1 and D2 trials)
Number of subjects: 9
Study 10223267 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E
Number of subjects: 9
Study 7752319 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Dornier HM3 lithotriptor
Number of subjects: 198
Study 7752319 — intervention group
Group type: COMPARATOR
Intervention: MFL 5000 lithotriptor
Number of subjects: 198
Study 1968710 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 24
Study 1968710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 349684 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 4
Study 349684 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoxydent
Number of subjects: 4
Study 349684 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptic
Number of subjects: 4
Study 349684 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise Cap
Number of subjects: 4
Study 349684 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional cusps (overall observation)
Number of subjects: 4
Study 31911072 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual continuous theta burst stimulation (cTBS) over left inferior frontal gyrus (IFG‐L) and right inferior parietal gyrus (IPL‐R)
Number of subjects: 46
Study 31911072 — intervention group
Group type: EXPERIMENTAL
Intervention: Single site IPL‐R cTBS
Number of subjects: 46
Study 31911072 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual cTBS
Number of subjects: 46
Study 31911072 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 46
Study 31911072 — intervention group
Group type: EXPERIMENTAL
Intervention: Single site IFG‐L cTBS
Number of subjects: 46
Study 28166861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity therapy (DT) + standard palliative care (SPC)
Number of subjects: 80
Study 28166861 — intervention group
Group type: COMPARATOR
Intervention: Standard palliative care (SPC)
Number of subjects: 80
Study 25640411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 65
Study 23930866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 75
Study 23930866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg
Number of subjects: 75
Study 23930866 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 75
Study 21675876 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program with exercise (nicotine replacement therapy, behavioral counseling, exercise prescription)
Number of subjects: 130
Study 21675876 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program with exercise
Number of subjects: 130
Study 19131322 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive treatment
Number of subjects: 0
Study 16925377 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated-humidified carbon dioxide insufflation
Number of subjects: 50
Study 16925377 — intervention group
Group type: COMPARATOR
Intervention: Cold-dry carbon dioxide insufflation
Number of subjects: 50
Study 15673999 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose multivitamin/mineral supplement
Number of subjects: 20
Study 15673999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15673999 — intervention group
Group type: COMPARATOR
Intervention: Control group of typical children
Number of subjects: 20
Study 11201778 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tobramycin 0.3%
Number of subjects: 43
Study 11201778 — intervention group
Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3%
Number of subjects: 43
Study 9010042 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt) with tamoxifen
Number of subjects: 211
Study 9010042 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt) without tamoxifen
Number of subjects: 211
Study 8504495 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 TIMI perfusion
Number of subjects: 298
Study 8504495 — intervention group
Group type: COMPARATOR
Intervention: Grade 2 TIMI perfusion
Number of subjects: 298
Study 8504495 — intervention group
Group type: COMPARATOR
Intervention: Grades 0/1 TIMI perfusion
Number of subjects: 298
Study 3113222 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of rt-PA
Number of subjects: 123
Study 3113222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 3113222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 123
Study 3113222 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with patent arteries on both previous angiograms
Number of subjects: 123
Study 31307836 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell (RBC) transfusion
Number of subjects: 60
Study 30291280 — intervention group
Group type: EXPERIMENTAL
Intervention: mid-VLPFC target (rTMS at left pars triangularis)
Number of subjects: 0
Study 30291280 — intervention group
Group type: EXPERIMENTAL
Intervention: parietal target (rTMS at left AG)
Number of subjects: 0
Study 30291280 — intervention group
Group type: COMPARATOR
Intervention: placebo control (rTMS at somatosensory cortex)
Number of subjects: 0
Study 26836245 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg vaginal E2 softgel capsules
Number of subjects: 50
Study 26836245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24634444 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (n = 60)
Number of subjects: 120
Study 24634444 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (n = 60)
Number of subjects: 120
Study 24627787 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5mg
Number of subjects: 23
Study 24627787 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5mg
Number of subjects: 23
Study 24627787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24627787 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (both doses)
Number of subjects: 23
Study 24627787 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine and Placebo
Number of subjects: 23
Study 20070250 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 3 months (statin‐treated, ST n=39)
Number of subjects: 56
Study 20070250 — intervention group
Group type: COMPARATOR
Intervention: Previous therapy (statin‐free, SF)
Number of subjects: 56